Introduction: Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is an innovative method for the unilateral treatment of essential tremor (ET) and Parkinson's disease (PD) related tremor. Our aim was to assess cognitive changes following MRgFUS thalamotomy to better investigate its safety profile. Methods: We prospectively investigated the cognitive and neurobehavioral profile of patients consecutively un-dergoing MRgFUS within a 2-year period. Patients had a comprehensive clinical and neuropsychological assessment before and six months after MRgFUS thalamotomy. Results: The final sample consisted of 40 patients (males 38; mean age +/- SD 67.7 +/- 10.7; mean disease duration +/- SD 9.3 +/- 5.6; ET 22, PD 18 patients). For the whole sample, improvements were detected in tremor (Fahn-Tolosa-Marin Clinical Rating Scale for tremor 35.79 +/- 14.39 vs 23.03 +/- 10.95; p < 0.001), anxiety feelings (Hamilton Anxiety rating scale 5.36 +/- 3.80 vs 2.54 +/- 3.28, p < 0.001), in the overall cognitive status (MMSE 25.93 +/- 3.76 vs 27.54 +/- 2.46, p 0.003; MOCA 22.80 +/- 4.08 vs 24.48 +/- 3.13, p < 0.001), and in quality of life (Quality of life in Essential Tremor Questionnaire 36.14 +/- 12.91 vs 5.14 +/- 6.90, p < 0.001 and PD Questionnaire-8 5.61 +/- 4.65 vs 1.39 +/- 2.33, p 0.001). No changes were detected in frontal and executive functions, verbal fluency and memory, abstract reasoning and problem-solving abilities. Conclusion: Our study moves a step forward in establishing the cognitive sequelae of MRgFUS thalamotomy and in endorsing effectiveness and safety.

Cognitive outcomes after focused ultrasound thalamotomy for tremor: Results from the COGNIFUS (COGNitive in Focused UltraSound) study

Saporito, Gennaro;Ornello, Raffaele;Bruno, Federico;Splendiani, Alessandra;Masciocchi, Carlo;Marini, Carmine;Sacco, Simona;Pistoia, Francesca
2023-01-01

Abstract

Introduction: Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is an innovative method for the unilateral treatment of essential tremor (ET) and Parkinson's disease (PD) related tremor. Our aim was to assess cognitive changes following MRgFUS thalamotomy to better investigate its safety profile. Methods: We prospectively investigated the cognitive and neurobehavioral profile of patients consecutively un-dergoing MRgFUS within a 2-year period. Patients had a comprehensive clinical and neuropsychological assessment before and six months after MRgFUS thalamotomy. Results: The final sample consisted of 40 patients (males 38; mean age +/- SD 67.7 +/- 10.7; mean disease duration +/- SD 9.3 +/- 5.6; ET 22, PD 18 patients). For the whole sample, improvements were detected in tremor (Fahn-Tolosa-Marin Clinical Rating Scale for tremor 35.79 +/- 14.39 vs 23.03 +/- 10.95; p < 0.001), anxiety feelings (Hamilton Anxiety rating scale 5.36 +/- 3.80 vs 2.54 +/- 3.28, p < 0.001), in the overall cognitive status (MMSE 25.93 +/- 3.76 vs 27.54 +/- 2.46, p 0.003; MOCA 22.80 +/- 4.08 vs 24.48 +/- 3.13, p < 0.001), and in quality of life (Quality of life in Essential Tremor Questionnaire 36.14 +/- 12.91 vs 5.14 +/- 6.90, p < 0.001 and PD Questionnaire-8 5.61 +/- 4.65 vs 1.39 +/- 2.33, p 0.001). No changes were detected in frontal and executive functions, verbal fluency and memory, abstract reasoning and problem-solving abilities. Conclusion: Our study moves a step forward in establishing the cognitive sequelae of MRgFUS thalamotomy and in endorsing effectiveness and safety.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/200059
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact